Search clinical trials for: Pembrolizumab and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）

Total 8688 results

Peking Union Medical College Hospital

Recruiting

Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Biliary Tract Neoplasms Immunotherapy

China
Shandong Cancer Hospital and Institute

Recruiting

First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC

Intrahepatic Cholangiocarcinoma

China
Prof. Massimo Aglietta

Completed

Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX)Versus GEMOX Alone to Treat Advanced Biliary Tract Adenocarcinoma (Vecti-BIL)

Biliary Carcinoma

Italy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)

Biliary Tract Cancer | Gemox Chemotherapy

China
Zhiyong Huang

Not yet recruiting

Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
University of Rochester
Amgen

Completed

Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer (UGIH09067)

Biliary Tract Cancer | Gallbladder Cancer

United States
Institut du Cancer de Montpellier - Val d'Aurelle

Completed

Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer (BREGO)

Digestive Cancer

France
University Hospital, Montpellier
Federation Francophone de Cancerologie Digestive

Recruiting

Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma (GEMOXIA-02)

Cholangiocarcinoma Non-resectable | Non-metastatic

France
University of Zurich

Terminated

Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer

Pancreatic Cancer

France, Switzerland, Belgium, Germany
Peking University

Unknown

Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

China
Nationwide Children's Hospital

Completed

Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

CNS Germ Cell Tumor

United States
Association of Research on the Biology of Liver...

Completed

Cetuximab + Gemox in Biliary Tract Cancer

Metastatic | Locally Advanced | Unresectable

Austria
M.D. Anderson Cancer Center
Sanofi-Synthelabo

Completed

Gemox as First and Second Line Therapy in Unknown Primary Cancer

Unknown Primary Neoplasms

United States
Shu-Zhong Cui
Guangdong Provincial Hospital of Traditional Chinese Medicine; Chinese PLA... and other collaborators

Unknown

Efficacy of HIPEC Combined With Systemic Chemotherapy and CRS on Peritoneal Metastases From Gastric Cancer

Gastric Cancer | Peritoneal Carcinomatosis

China
AstraZeneca

Recruiting

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (TOURMALINE)

Biliary Tract Cancer

France, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
Peking Union Medical College Hospital

Recruiting

Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Biliary Tract Neoplasms Immunotherapy

China
Zhejiang Cancer Hospital

Recruiting

GOT Applied as Neoadjuvant Regimen for Patients of Resectable ICC With High-risk Factors of Recurrence (GOT)

Intrahepatic Cholangiocarcinoma

China
Fudan University

Completed

Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles

Colorectal Cancer

China
Lymphoma Study Association
Eli Lilly and Company; Hoffmann-La Roche; Sanofi-Synthelabo

Completed

Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma

Diffuse Large Cell Lymphoma

France
Sun Yat-sen University

Unknown

Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL

Lymphoma, Extranodal NK-T-Cell

China
Guangxi Medical University

Withdrawn

Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma

Hepatocellular Carcinoma
Kyowa Kirin, Inc.

Completed

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Adult T-cell Leukemia-Lymphoma

United States, United Kingdom, Belgium, France, Brazil, Peru
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC (KN035-BTC)

Biliary Tract Neoplasms

China
Antengene Corporation

Recruiting

A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma (TOUCH)

Peripheral T-cell Lymphoma | NK/T-cell Lymphoma

China
Shanghai Zhongshan Hospital

Active, not recruiting

Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma, Intrahepatic

China
Hospices Civils de Lyon

Completed

MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents (MGMT-NET)

Neuroendocrine Tumors

France
The Lymphoma Academic Research Organisation
Innate Pharma

Recruiting

Study of Lacutamab in Peripheral T-cell Lymphoma

Peripheral T Cell Lymphoma | Relapse/Recurrence

France, Spain, Belgium, Germany
Yixing People's Hospital

Recruiting

Efficacy and Safety of Tirelizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Lymph Node Positive Gastric Cancer After Surgery

Gastric Cancer

China
University of Erlangen-Nürnberg Medical School

Completed

Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy (CONKO-007)

Pancreatic Cancer

Germany
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Bladder Urothelial Carcinoma In Situ | Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Invasive Bladder Mixed Carcinoma

United States, Guam, Puerto Rico
Fudan University

Not yet recruiting

Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma
The First Affiliated Hospital with Nanjing Medical...

Unknown

Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.

Diffuse Large B-cell Lymphoma
Sun Yat-sen University

Not yet recruiting

Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma (O-Gemox)

DLBCL

China
Sichuan University

Not yet recruiting

Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC

Combined Hepatocellular Cholangiocarcinoma
Tianjin Medical University Cancer Institute and...

Recruiting

Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.

Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

China
Miltenyi Biomedicine GmbH
ICON plc

Recruiting

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU)

Diffuse Large B-cell Lymphoma

Spain, Germany, Netherlands, Belgium, France, Czechia, Austria, Lithuania, Sweden, Hungary, Italy, Poland
University of California, Irvine

Terminated

Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer

Carcinoma, Transitional Cell

United States
Sun Yat-sen University

Recruiting

Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type

NK/T Cell Lymphoma Nos

China
University Hospital, Brest
Groupe Français de Pneumo-Cancérologie

Recruiting

PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % (PERSEE)

Non-small-cell Lung Cancer

France
Shanghai Zhongshan Hospital

Unknown

Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma

China
Shanghai Zhongshan Hospital

Active, not recruiting

Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma, Intrahepatic

China
Xiaorong Dong

Unknown

Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy

NSCLC | Chemotherapy | Gut Microbiota | Pembrolizumab
Assistance Publique - Hôpitaux de Paris

Terminated

Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study (THYGEMOX)

Thyroid Cancer

France
Xu jianmin

Unknown

Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer

Neoplasm Metastasis | Liver Neoplasms | Colorectal Neoplasms

China
University Hospital Tuebingen
Icahn School of Medicine at Mount Sinai

Unknown

Study of Plasma Tumor-promoting Factors and Immune Function After Laparotomy, Cytoreductive Surgery and HIPEC vs. PIPAC in Patients With Peritoneal Metastasis (IMMUNOPAC)

Peritoneal Cancer | Chemotherapy-Induced Change

Germany
Sanofi

Completed

Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States
Yuankai Shi

Completed

Study of Pembrolizumab Combined With Chemotherapy in the First Line Therapy for R/M HNSCC in China

Head and Neck Squamous Cell Carcinoma

China
University of Hawaii

Withdrawn

Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1

Metastatic Pancreatic Cancer | ERCC1

United States
Sun Yat-sen University

Active, not recruiting

Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer

Advanced Rectal Cancer

China
Fudan University
Second Affiliated Hospital, School of Medicine, Zhejiang University; Ruijin... and other collaborators

Unknown

Trial of Preoperative Hepatic and Regional Arterial Chemotherapy (PHRAC) to Prevent Postoperative Liver Metastasis of Colorectal Cancer (PHRAC)

Colorectal Neoplasms

China

3

Subscribe